Novo Nordisk ADR (NYSE:NVO)’s traded shares stood at 4.45 million during the last session, with the company’s beta value hitting 0.42. At the close of trading, the stock’s price was $113.38, to imply a decrease of -0.47% or -$0.54 in intraday trading. The NVO share’s 52-week high remains $148.15, putting it -30.67% down since that peak but still an impressive 18.03% since price per share fell to its 52-week low of $92.94. The company has a valuation of $378.51B, with an average of 3.51 million shares in intraday trading volume over the past 10 days and average of 3.98 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Novo Nordisk ADR (NVO), translating to a mean rating of 1.94. Of 5 analyst(s) looking at the stock, 0 analyst(s) give NVO a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.88.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR (NYSE:NVO) trade information
After registering a -0.47% downside in the last session, Novo Nordisk ADR (NVO) has traded red over the past five days. The 5-day price performance for the stock is -3.99%, and -8.79% over 30 days. With these gigs, the year-to-date price performance is 9.60%. Short interest in Novo Nordisk ADR (NYSE:NVO) saw shorts transact 7.03 million shares and set a 1.82 days time to cover.
The extremes give us $156 and $160 for target low and target high price respectively. As such, NVO has been trading -41.12% off suggested target high and -37.59% from its likely low.
Novo Nordisk ADR (NVO) estimates and forecasts
Looking at statistics comparing Novo Nordisk ADR share performance against respective industry, we note that the company has outperformed competitors. Novo Nordisk ADR (NVO) shares are -10.62% down over the last 6 months, with its year-to-date growth rate higher than industry average at 13.70% against 6.30%. Revenue is forecast to grow 20.50% this quarter before jumping 27.10% for the next one. The rating firms project that company’s revenue will grow 25.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 10.42B. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 11.47B.Earnings reports from the last fiscal year show that sales brought in 8.55B and 9.4B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 22.00% before jumping 22.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 16.48% for the past 5-year period. While 2024 is set for a 23.67% return in earnings, projections for the next 5 years are at 18.21% annually.
NVO Dividends
Novo Nordisk ADR has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Novo Nordisk ADR has a forward dividend ratio of 1.45, with the share yield ticking at 1.28% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 1.48%.
The next major institution holding the largest number of shares is FMR LLC with 19.49 million shares, or about 0.4371% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.78 billion.
We also have Harbor Capital Appreciation Fund and Washington Mutual Investors Fund as the top two Mutual Funds with the largest holdings of the Novo Nordisk ADR (NVO) shares. Going by data provided on Jul 31, 2024 , Harbor Capital Appreciation Fund holds roughly 4.68 shares. This is just over 0.14% of the total shares, with a market valuation of $530.54 million. Data from the same date shows that the other fund manager holds a little less at 3.94, or 0.12% of the shares, all valued at about 446.82 million.
